BUSINESS

Taiyo to Be Core of Teva’s Operations in Japan

January 16, 2012
Taiyo Pharmaceutical Industry has joined Teva-Kowa Pharmaceutical as a subsidiary of Teva Pharmaceutical Industries of Israel, the world’s largest generic drug manufacturer. With combined sales of approximately ¥70 billion in FY2010 (Taiyo ¥51 billion, Teva-Kowa ¥18 billion) the two companies…

To read the full story

BUSINESS

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…

By Ken Yoshino

As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…